Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Company Overview

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other serious medical conditions. The company’s best-known product is Endari (L-glutamine) oral powder, which was approved by the U.S. Food and Drug Administration in 2017 to reduce acute complications associated with sickle cell disease in adults and children aged five and older.

Emmaus has also pursued research programs involving metabolic, gastrointestinal and other rare disorders, including therapies intended to address conditions with limited treatment options. Its activities have included product development, regulatory submissions and commercialization efforts in the United States and selected international markets.

The company was founded by physician and researcher Yutaka Niihara, who has served as its chief executive officer and has been closely associated with its sickle cell disease program. Information about Emmaus’ current operations, product portfolio and leadership may change as the company’s business develops.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.01 to $0.08
• 52-Week Range: $0.01 to $0.09
• Volume: 110,891 shs
• Average Volume: 151,689 shs
• Market Capitalization: $4.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Emmaus Life Sciences Stock Analysis - MarketRank™

Emmaus Life Sciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Emmaus Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Emmaus Life Sciences is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Emmaus Life Sciences is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of Emmaus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Emmaus Life Sciences has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Emmaus Life Sciences has recently increased by 610.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Emmaus Life Sciences does not currently pay a dividend.

Dividend Growth

Emmaus Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: N/A

News Sentiment

Emmaus Life Sciences has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.42% of the stock of Emmaus Life Sciences is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:EMMA
• CIK: 822370
• Web: www.emmausmedical.com
• Phone: (310) 214-0065
• Fax: 866-294-2611
• Employees: 33
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.49 million
• Net Margins: -38.78%
• Pretax Margin: -34.93%
• Return on Equity: N/A
• Return on Assets: -31.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $12.45 million
• Price / Sales: 0.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.91) per share
• Price / Book: -0.07

Miscellaneous

• Outstanding Shares: 70,190,000
• Free Float: 45,622,000
• Market Cap: $4.77 million
• Optionable: Not Optionable
• Beta: 10.07